These results suggested that the KAT5-circSMARCA5-miR-181b-5p-TIMP3 and/or KAT5-circSMARCA5-miR-17-3p-TIMP3 axis might represent a novel target for prostate cancer therapy. This evidence concerns the gene KAT5 and prostate cancer.